Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.Insulin sensitivity and fertility.Measuring the acute effect of insulin infusion on ATP turnover rate in human skeletal muscle using phosphorus-31 magnetic resonance saturation transfer spectroscopy.Effects of raising muscle glycogen synthesis rate on skeletal muscle ATP turnover rate in type 2 diabetes.Altered volume, morphology and composition of the pancreas in type 2 diabetes.The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial.Quantification of intrapancreatic fat in type 2 diabetes by MRI.Increased daily walking improves lipid oxidation without changes in mitochondrial function in type 2 diabetes.Morphology of the pancreas in type 2 diabetes: effect of weight loss with or without normalisation of insulin secretory capacity.Type 2 diabetes, bariatric surgery and the risk of subsequent gestational diabetesIntrauterine growth rate in pregnancies complicated by type 1, type 2 and gestational diabetes.Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers.Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction.Use of adipose tissue for metabolic studies.Glucose homoeostasis in chronic liver disease.Management of non-insulin-dependent diabetes.Insulin sensitivity in experimental cirrhosis.Normal weight individuals who develop type 2 diabetes: the personal fat threshold.Post-prandial thermogenesis and insulin sensitivity in the polycystic ovary syndrome.Adipocyte insulin binding and insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis.Dietary reversal of Type 2 diabetes motivated by research knowledge.Tissue insulin sensitivity and body weight in polycystic ovary syndrome.Causation of type 2 diabetes -- the Gordian knot unravels.Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.Population response to information on reversibility of Type 2 diabetes.Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes.Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders.Reversal of Type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes.Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in Type 2 diabetes.Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes.Pancreatic triacylglycerol distribution in type 2 diabetes.In vitro study of human skeletal muscle strips: effect of nonesterified fatty acid supply on glucose storage.Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell RecoveryRemission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell RecoveryVLCD for weight loss and remission of type 2 diabetes? - Authors' replyCan type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number oneCalorie restriction for long-term remission of type 2 diabetesCatastrophic circulatory collapse following re-expansion pulmonary oedemaInsulin resistance: circumventing nature's blocks
P50
Q34191173-5A827131-FD94-4C60-AD58-E5586B694F64Q34530589-F288192A-0E5D-4895-AEFE-3FA6D5907FBDQ35062009-622858E0-41B0-412A-82E8-449792EBBDE9Q35601244-86BCFF85-FB05-4D01-976B-BC9D728563C1Q35623969-62BD320D-AA4C-4C3F-A6AE-77D986C6359CQ35924358-945DECE9-716C-4CDD-B126-C81AF28EC742Q36331867-2DA51A3A-B73C-4407-97B8-ECDDBA1C3215Q36807542-78CE9977-3F97-4222-9354-D99EC9A4E844Q37059330-3348598D-62AD-407F-A237-4A19BE97D346Q37185981-4093C4DE-564F-4740-AD12-458E42584E68Q37186479-0285C318-CFD2-43AD-9360-D85BD7B907EDQ37541501-201A00E8-32C9-4FD0-9EAB-1757A49D90C5Q38787752-0276CFCB-6902-4C63-B31D-01BE13B2B8E6Q39031698-A570A4A5-B813-4D8B-BC3B-8882D278A6DEQ39700076-FFB15B97-93B8-4B2A-9C46-28BF2EB02AF1Q39731666-0645BAF4-5051-4988-A7F6-BCCAC9C93D49Q40442601-3CBBFE81-9132-4EA2-BC70-BF347EF540C9Q41225251-4C925D52-9538-43FD-AFF5-530AEE7C28F2Q41682743-76EA6A75-437C-4564-9ADF-BD80B994AE52Q42011688-8CA400B5-91D6-4A0C-8E19-AE4032DCBBDCQ42521470-BDD8F1C5-6B33-4440-BEB6-0AD5D9579637Q43025039-8D040686-4426-4096-8D73-2D92CE5DD17DQ43725577-66E4E64F-E422-416B-967B-5B86899C9795Q44762767-A8861D8F-ACEC-47A8-AC3C-813F60CE0F5EQ45161702-AD97942F-EAC1-483F-99A4-D9E8BCAD5F9DQ45230775-20C6D889-78DD-44CF-84D2-0690EBDFC0C2Q46554159-9236401E-55E8-4A3F-B749-6DC159C4D71BQ47316631-A12231E2-2744-4E51-89E5-F15138965B0FQ47442006-C3ECE2C2-968E-49E3-94A9-8678AEE679CDQ50259673-A59F1780-8A6F-4DCF-808D-D25761E563BEQ51307865-80611675-EFF2-4FF0-9C78-DFF943C2DA9BQ53399004-3B5D8AF6-7595-4CBA-A0B5-A3DC6C437EFBQ54339293-EC07B4B8-73F1-4B46-B063-633093015548Q57044693-C2A2F872-26FB-4052-A4B0-0C369548F72CQ57044759-1470D20D-EEDD-41C9-BB0D-27FB5E4BC3E9Q57469146-DF2A2AAB-2C68-455E-9AF2-265F4C494A58Q58087664-5A6E38F2-D985-428F-82B7-F5BEB32E30F0Q64237221-D7395B6E-455E-4AEF-A2D2-C35B45397646Q71475025-7CBCEA6F-03BA-4237-A4F5-20272AA3A078Q71693065-B0479993-8025-45DD-A3B7-F5350FDD7FE8
P50
description
physician and diabetologist and researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roy Taylor
@ast
Roy Taylor
@en
Roy Taylor
@es
Roy Taylor
@nl
Roy Taylor
@sl
type
label
Roy Taylor
@ast
Roy Taylor
@en
Roy Taylor
@es
Roy Taylor
@nl
Roy Taylor
@sl
prefLabel
Roy Taylor
@ast
Roy Taylor
@en
Roy Taylor
@es
Roy Taylor
@nl
Roy Taylor
@sl
P214
P244
P106
P21
P214
P244
n2006180175
P31
P496
0000-0001-6273-0170
P734
P7859
lccn-n2006180175